drugset / Trial / NCT06417099

Efficacy of Dihydroartemisinin for Treating PCOS

NCT06417099

Phase 2 Completed 30 enrolled Shanghai Zhongshan Hospital
NaSingle-groupOpen-labelTreatment

Summary

The primary research hypothesis of this study is that dihydroartemisinin is effective in restoration of regular menstrual cycles of PCOS subjects who meet at least two of three Rotterdam Criteria. Secondary research hypotheses include: dihydroartemisinin is also effective in reducing androgen, total immature follicles, and anti-Mullerian hormone.

Timeline

Start
2024-05-24
Primary completion
2025-03-30
Completion
2025-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ARTENIMOL Small molecule 40 mg Oral